Drugs Losing Exclusivity in 2030 & Key Intermediates
19 drugs expire in 2030 (public sources), 17 with recorded synthesis routes; key intermediates of 14 drugs are already available through the Unibest supply network. Generic developers typically secure intermediate supply 2–3 years ahead — use this table for shortlisting and RFQ.
| Drug | Tier | Expiry | Indications | Routes | CAS count | Available |
|---|---|---|---|---|---|---|
| 非奈利酮 Finerenone | C · Watch | 2030 | 收缩性心力衰竭、舒张期心力衰竭、心脏衰竭 | 35 | 96 | Available ×96 |
| 维奈克拉 Venetoclax | B · Position early | 2030 | 急性髓细胞样白血病、慢性淋巴细胞白血病 | 3 | 31 | Available ×31 |
| 阿来替尼盐酸盐 Alectinib Hydrochloride | B · Position early | 2030 | 非小细胞肺癌、肺癌 | 3 | 30 | Available ×30 |
| 阿帕他胺 Apalutamide | A · Act now | 2030 | 去势抵抗性前列腺肿瘤、前列腺癌 | 2 | 20 | Available ×20 |
| 阿可替尼 Acalabrutinib | A · Act now | 2030 | 套细胞淋巴瘤、慢性淋巴细胞白血病、淋巴细胞性白血病 | 2 | 14 | Available ×14 |
| 恩曲替尼 Entrectinib | C · Watch | 2030 | 实体瘤、非小细胞肺癌 | 1 | 14 | Available ×14 |
| 苯磺酸美洛加巴林 Mirogabalin besilate | C · Watch | 2030 | 糖尿病神经病变、疱疹后神经痛、周围神经系统疾病 | 2 | 14 | Available ×14 |
| 马来酸阿伐曲泊帕 Avatrombopag Maleate | C · Watch | 2030 | 血小板减少、特发性血小板减少性紫癜、肝脏疾病 | 1 | 11 | Available ×11 |
| 图卡替尼 Tucatinib | C · Watch | 2030 | 乳腺癌、结直肠癌 | 1 | 10 | Available ×10 |
| 马来酸奈拉替尼 Neratinib Maleate | C · Watch | 2030 | 乳腺癌 | 4 | 30 | Available ×3 |
| 恩考芬尼 Encorafenib | C · Watch | 2030 | 非小细胞肺癌、结直肠癌、甲状腺瘤 | 1 | 23 | Available ×2 |
| 伐度司他 Vadadustat | C · Watch | 2030 | 慢性肾功能不全、贫血 | 2 | 12 | Available ×1 |
| 甲苯磺酸奥马环素 Omadacycline tosylate | C · Watch | 2030 | 皮肤和皮肤结构感染、社区获得性细菌肺炎、细菌感染 | 3 | 14 | Available ×1 |
| 厄达替尼 Erdafitinib | C · Watch | 2030 | 尿路上皮癌、泌尿系肿瘤 | 3 | 18 | Available ×1 |
| 达格列净丙二醇/盐酸二甲双胍 Dapagliflozin Propanediol/Metformin Hydrochloride | A · Act now | 2030 | 二型糖尿病 | - | - | - |
| 洛拉替尼 Lorlatinib | B · Position early | 2030 | 非小细胞肺癌 | 2 | 20 | - |
| 塞利尼索 Selinexor | C · Watch | 2030 | 弥漫性大B-细胞淋巴瘤、多发性骨髓瘤 | 1 | 7 | - |
| 苯磺酸瑞马唑仑 Remimazolam Besilate | C · Watch | 2030 | 镇静、麻醉 | 1 | 9 | - |
| 艾拉环素 Eravacycline | C · Watch | 2030 | 新型冠状病毒感染 | - | - | - |
Frequently asked questions
Which drugs lose exclusivity in 2030?
19 drugs expire in 2030 per public sources: Dapagliflozin Propanediol/Metformin Hydrochloride, Alectinib Hydrochloride, Lorlatinib, Venetoclax, Acalabrutinib, Entrectinib, etc.
When should we start sourcing intermediates for 2030 launches?
Generic developers typically secure development-scale supply 2–3 years before expiry. 14 of the 19 drugs in this table already have on-sale intermediates in the Unibest network; the rest can be RFQ'd per CAS.
Are route and CAS data verified?
All fields are structured data cross-verified from public sources; intermediates carry registry codes and CAS numbers, and every "Available" badge links to real listings.
Source: cross-verified structured fields · Expiry years are public-source estimates; consult individual agencies for authoritative dates · 2026-09-24